ctDNA-based molecular residual disease and survival in resectable colorectal cancer
Nakamura, et al. Nature Medicine 2024
Read More
Signatera
Resources related to Signatera residual disease testing from a simple drop of blood.
-
-
Recio Study 1 Page
Read More
-
Signatera Sample Collection
Watch Video
-
New Data Review Can treating molecular residual disease (MRD) in colorectal cancer improve outcomes
Watch Video
-
A Rare Cancer, A Powerful Tool: What the New Guidelines Mean for Merkel Cell Carcinoma Patients
Read Article
-
How MRD Testing Supports Colorectal Cancer Patients: Jason’s Story and the Importance of Regular Monitoring
Read Article
-
Jason's Patient Testimonial
Watch Video
-
MRD Testing in NSCLC to Personalize Patient Care
Watch Video
-
Unlocking new uses for old drugs
a revolution in precision oncology using evidence-based MRD testing
Watch Video
-
Medicare Expands Coverage of Signatera for Patients with Lung Cancer
Read Article
-
How to Use Natera’s Patient Portal to Manage Your Cancer Care
Read Article
-
What Is MRD Testing and How Can It Help Monitor Cancer Recurrence?
Read Article
-
New data: Optimizing breast cancer care and drug development with molecular residual disease testing
Watch Video
-
Signatera for Colorectal Liver Metastases
Read More
-
Natera at SABCS 2024: What It Means for Breast Cancer Survivors
Read Article
-
How to Talk to Your Doctor About Signatera for Lung Cancer
Learn how to talk to your doctor about Signatera for lung cancer recurrence monitoring. Understand the benefits of ctDNA testing, how it detects recurrence early, and why it’s vital for personalized c
Read Article
-
The Tipping Point: How clinically validated MRD testing is transforming patient management in colorectal cancer
Watch Video
-
Utilization of Circulating Tumor DNA in the Surveillance Setting
Gibbs JN, Dale PS, Weatherall AL. The American Surgeon. 2023
Read More
-
Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors
Kalashnikova E, Aushev, VA, Malashevich AK, et al. Molecular Oncology. 2023
Read More
-
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
Tsimberidou AM, Alayli FA, Okrah K, et al. Journal of Experimental Medicine. 2024
Read More
-
Loading More...
